Trial Profile
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics
- Sponsors Eisai Co Ltd
- 08 Feb 2021 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Sep 2020.
- 11 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.